Cereno Scientific AB

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Last month, Merck & Co., Inc. ’s Winrevair (sotatercept) became the first disease-modifying therapy approved for pulmonary arterial hypertension (PAH) and expectations for the product are high, with